Rapid Critical Metals (RLL:AU) has announced Strategic EL Secured -Expands Control of NSW Silver Corridor
Download the PDF here.
This post appeared first on investingnews.com
Keith Weiner, founder and CEO of Monetary Metals, discusses gold and silver’s performance so far this year and shares his outlook for the rest of 2025.
He also explains what makes today’s gold bull market different than those seen in prior years.
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is still trading at three-year highs, despite current market volatility, in response to breakthrough innovations and increased deals involving biotech stocks listed on the NASDAQ.
After dropping to a low of 3,637.05 in October 2023, the index climbed to a nearly three year peak of 4,954.813 on September 19, 2024. While the index had pulled back to 4,530.69 as of August 5, 2025, further growth could be in store in the future.
According to a Towards Healthcare analyst report, the global biotech market is expected to grow at a compound annual growth rate of 12.5 percent from now to 2034, reaching a valuation of US$5.04 trillion.
Driving that growth will be favorable government policies, investment in the sector, increased demand for synthetic biology and a rise in chronic disorders such as cancer, heart disease and hypertension.
The top NASDAQ biotech stocks have seen sizeable share price increases over the past year. For those interested in investing in biotech companies, the best-performing small-cap biotech stocks are outlined below.
Data was gathered on August 5, 2025, using TradingView’s stock screener. Small-cap biotech stocks with market caps between US$50 million and US$500 million at that time were considered for this list.
1. Tiziana Life Sciences (NASDAQ:TLSA)
Year-to-date gain: 227.8 percent
Market cap: US$256.36 million
Share price: US$2.26
Tiziana Life Sciences is a clinical-stage biopharma which is developing therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its pipeline of candidates is built on its patent drug delivery technology that provides a possible alternative to intravenous delivery. Tiziana’s lead candidate is intranasal foralumab, a fully human anti-CD3 monoclonal antibody.
Tiziana Life Sciences shares hit US$1.69 on March 7 after the company filed its investigational new drug application to the US Food and Drug Administration (FDA) for a Phase 2 clinical trial in amyotrophic lateral sclerosis (ALS), which is supported by the ALS Association. However, by early April that value had fallen back to US$0.78 per share.
A series of positive news flow later in the spring helped to give Tiziana shares another boost. In April, John Hopkins University and the University of Massachusetts commenced dosing of the biotech company’s intranasal foralumab in Phase 2 trials for patients with non-active secondary progressive multiple sclerosis. On May 7, the company shared positive results from the use of its lead candidate in improving the quality of life for patients with that form of multiple sclerosis.
Tiziana is also studying the use of intranasal foralumab for treating moderate Alzheimer’s disease. On May 9, it announced that PET scans of a patient with moderate Alzheimer’s showed a significant reduction in microglia activation associated with neuroinflammation after three months of treatment.
Shares of Tiziana reached US$1.62 on May 13.
On July 21, the company announced an ‘unexpected discovery’ in its findings of an immunologic analysis of the patient with Alzheimer’s disease.
‘In an unexpected discovery, the analysis revealed an increase in phagocytosis markers in classical monocytes, suggesting that nasal foralumab may enhance their ability to clear amyloid plaques,’ the press release states. ‘This unexpected effect may open new avenues for treating Alzheimer’s Disease by targeting both inflammation and amyloid accumulation.’
Tiziana’s share price climbed through the remainder of the month, hitting a year-to-date high of US$2.50 on July 31.
2. Palvella Therapeutics (NASDAQ:PVLA)
Year-to-date gain: 224.98 percent
Market cap: US$416.08 million
Share price: US$37.64
Palvella Therapeutics is a clinical-stage biopharma developing treatments targeting rare genetic skin diseases for which there are no FDA-approved therapies. The company’s product pipeline centers on its patented QTORIN platform, which has an initial focus on rare genetic skin diseases.
Its lead product candidate, QTORIN rapamycin, is currently in a Phase 2 clinical trial in cutaneous venous malformations, and a Phase 3 clinical trial in microcystic lymphatic malformations (LM). QTORIN rapamycin has been granted breakthrough therapy designation, orphan drug designation and fast track designation from the FDA for the treatment of microcystic LMs.
After starting the year at US$12.00, shares of Palvella had surged to US$20.99 by February 18. About a week earlier, the company had shared plans to expand the Phase 3 trial to include pediatric patients from three to five years of age. That momentum in Palvella’s share price continued to rally to US$29 per share on March 13.
June produced a number of significant milestones for Palvella. On June 9, the company received initial proceedings from a grant issued by the FDA Office of Orphan Products Development for its Phase 3 trial, and on June 23, it completed enrollment for the trial with 51 subjects, 25 percent over its target. The company closed out the month with news it was added to the broad-market Russell 3000 Index and the Russell 2000 Index.
The company said it remains on track to deliver top-line Phase 3 data in Q1 2026 to support its planned new drug application submission later that year.
While the company didn’t release news in July, Palvella Therapeutics’ share price climbed significantly through the month to hit a year-to-date high of US$39.87 on July 28.
3. OKYO Pharma (NASDAQ:OKYO)
Year-to-date gain: 163.03 percent
Market cap: US$117.35 million
Share price: US$3.13
OKYO Pharma is a clinical-stage biopharma developing therapies for the treatment of neuropathic corneal pain and dry eye disease. Its lead candidate is urcosimod, a non-steroidal anti-inflammatory and non-opioid analgesic.
So far in 2025, the company has achieved multiple milestones related to its Phase 2 trial of urcosimod for treatment of neuropathic corneal pain.
On April 30, OKYO announced plans to end the trial early to analyze the data from the patients who had completed the trial, with the goal of accelerating its clinical development and expanding the program. Supporting the decision was the fact that urcosimod had previously demonstrated safety in OKYO’s completed Phase 2 trial of the candidate to treat patients with dry eye disease.
The next day, news broke that the FDA granted urcosimod fast track designation for the treatment of neuropathic corneal pain. OKYO’s stock price reached US$1.57 on May 1.
On July 17, OKYO posted strong top-line data from its Phase 2 clinical trial, and stated it is planning a meeting with the FDA to discuss next steps for its lead drug candidate. The following day, OKYO received US$1.9 million in non-dilutive funding to support its clinical development of urcosimod.
Shares of OKYO hit a year-to-date high of US$3.17 on August 5.
4. IO Biotech (NASDAQ:IOBT)
Year-to-date gain: 129.47 percent
Market cap: US$144.28 million
Share price: US$2.16
IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulating therapeutic cancer vaccines based on its T-win technology platform, designed to activate T cells to target both tumor cells and the immune-suppressive cells. The company’s lead cancer vaccine candidate IO102-IO103, which has the brand name Cylembio, is currently in clinical trials.
The FDA granted breakthrough therapy designation to IO102-IO103 when used in combination with Merck’s (NYSE:MRK) anti-PD-1 therapy KEYTRUDA for the treatment of advanced melanoma based on positive Phase 1/2 first line metastatic melanoma data.
At the start of the year, IO Biotech completed enrollment in its Phase 2 trial of IO102-IO103 with KEYTRUDA as a treatment given before and after surgery for resectable melanoma or head and neck cancer.
On February 4, the company published results from a preclinical study of its second immune-modulatory therapeutic cancer vaccine candidate, IO112, targeting arginase 1, which plays a key role in immune suppression.
In mid-March, IO Biotech was named to Fast Company’s list of the World’s Most Innovative Companies of 2025. The following month, the company presented new preclinical data for its lead candidate IO102-IO103 as well as IO170, which targets Transforming Growth Factor beta.
In its Q1 2025 financial results and business highlights released on May 14, IO Biotech shared that a readout of primary endpoint data from its pivotal Phase 3 trial of its lead investigational therapeutic cancer vaccine in patients with advanced melanoma is expected in the third quarter of 2025.
Shares of IO Biotech reached a year-to-date high of US$2.40 on July 28.
5. Spero Therapeutics (NASDAQ:SPRO)
Year-to-date gain: 110.95 percent
Market cap: US$124.12 million
Share price: US$2.22
Spero Therapeutics is developing novel treatments for rare diseases and multi-drug resistant bacterial infections with high unmet need. The company’s lead drug candidate is tebipenem pivoxil hydrobromide (HBr), a late-stage development asset developed in collaboration with pharma giant GSK (NYSE:GSK) to treat complicated urinary tract infections (cUTIs), including pyelonephritis.
Spero has an exclusive license agreement with GSK for the development and commercialization of the drug candidate in all ex-Asia markets. The FDA has granted tebipenem HBr qualified infectious disease product and fast track designations.
Shares in Spero traded below US$1.00 for much of the first half of 2025. However, the stock’s value surged 245 percent on May 28 to reach US$2.35 per share after Spero reported that its Phase 3 trial evaluating tebipenem HBr for treating cUTIs met its primary endpoint and stopped early for efficacy. GSK plans to include the findings in a filing to the FDA during H2.
Spero shares reached a year-to-date high of US$3.04 on July 9.
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
(TheNewswire)
TORONTO, ON, August 13, 2025 TheNewswire – Silver Crown Royalties Inc. ( Cboe: SCRI,OTC:SLCRF; OTCQX: SLCRF; FRA: QS0) ( ‘Silver Crown’ or the ‘Company’ ) is pleased to announce that, further to its press release dated August 7, 2025, it has closed the acquisition of a royalty on 90% of the cash equivalent of silver produced each quarter from the past producing Scotia Mine (the ‘Silver Royalty’ ) with EDM Resources Inc. ( TSX-V: EDM; FSE: P3Z) ( ‘EDM’ ). The Silver Royalty provides for minimum of the cash equivalent of 7,000 ounces per year for 10 years starting at commercial production on the Scotia Mine. SCRi paid $250,000 in cash at closing and issued 60,000 units (‘ Units ‘) to EDM per Unit at a deemed value of C$10.00, with each Unit consisting of a common share in the capital of SCRi (‘ Common Share ‘) and one warrant exercisable into an additional Common Share at a price of C$13.00 for a period of 36 months following the date hereof. SCRi must pay EDM an additional C$250,000 cash payment following the date hereof as deferred consideration for the Silver Royalty.
ABOUT EDM RESOURCES INC.
EDM Resources Inc. (‘EDM’) ( TSX-V: EDM; FSE: P3Z) is a Canadian exploration and mining company that has full ownership of the Scotia Mine and related facilities near Halifax, Nova Scotia. Through its wholly owned subsidiary, EDM also holds several prospective exploration licenses near its Scotia Mine and in the surrounding regions of Nova Scotia .
ABOUT Silver Crown Royalties INC.
Founded by seasoned industry professionals, Silver Crown Royalties ( Cboe: SCRI | OTCQX: SLCRF | FRA: QS0) is a publicly traded silver royalty company dedicated to generating free cash flow. Silver Crown (SCRi) currently holds five silver royalties. Its business model offers investors exposure to precious metals, providing a natural hedge against currency devaluation while mitigating the adverse effects of production-related cost inflation. SCRi strives to minimize the economic burden on mining projects while simultaneously maximizing shareholder returns. For further information, please contact:
Silver Crown Royalties Inc.
Peter Bures, Chairman and CEO
Telephone: (416) 481-1744
Email: pbures@silvercrownroyalties.com
FORWARD-LOOKING STATEMENTS
This release contains certain ‘forward looking statements’ and certain ‘forward-looking information’ as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as ‘may’, ‘will’, ‘should’, ‘expect’, ‘intend’, ‘estimate’, ‘anticipate’, ‘believe’, ‘continue’, ‘plans’ or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Forward-looking statements and information include, but are not limited to, SCRi must pay EDM an additional C$250,000 cash payment following the date hereof as deferred consideration for the Silver Royalty . Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual actions, events or results to be materially different from those expressed or implied by such forward-looking information, including but not limited to: the impact of general business and economic conditions; the absence of control over mining operations from which SCRi will purchase gold and other metals or from which it will receive royalty payments and risks related to those mining operations, including risks related to international operations, government and environmental regulation, delays in mine construction and operations, actual results of mining and current exploration activities, conclusions of economic evaluations and changes in project parameters as plans continue to be refined; accidents, equipment breakdowns, title matters, labor disputes or other unanticipated difficulties or interruptions in operations; SCRi’s ability to enter into definitive agreements and close proposed royalty transactions; the inherent uncertainties related to the valuations ascribed by SCRi to its royalty interests; problems inherent to the marketability of gold and other metals; the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; industry conditions, including fluctuations in the price of the primary commodities mined at such operations, fluctuations in foreign exchange rates and fluctuations in interest rates; government entities interpreting existing tax legislation or enacting new tax legislation in a way which adversely affects SCRi; stock market volatility; regulatory restrictions; liability, competition, the potential impact of epidemics, pandemics or other public health crises on SCRi’s business, operations and financial condition, loss of key employees. SCRi has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information. SCRi undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available.
This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities of the Company in Canada, the United States or any other jurisdiction. Any such offer to sell or solicitation of an offer to buy the securities described herein will be made only pursuant to subscription documentation between the Company and prospective purchasers. Any such offering will be made in reliance upon exemptions from the prospectus and registration requirements under applicable securities laws, pursuant to a subscription agreement to be entered into by the Company and prospective investors. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.
CBOE CANADA DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.
Copyright (c) 2025 TheNewswire – All rights reserved.
News Provided by TheNewsWire via QuoteMedia
This post appeared first on investingnews.com
Osisko Metals Incorporated (the ‘ Company or ‘ Osisko Metals ‘) ( TSX-V: OM ; OTCQX: OMZNF ; FRANKFURT: 0B51 ) is pleased to announce new drill results from the Gaspé Copper Project, located in the Gaspé Peninsula of Eastern Québec.
Osisko Metals Chief Executive Officer Robert Wares commented: ‘ Drill results at Gaspé Copper continue to exceed expectations. These new data expand the deposit further south and at depth with drill holes 30-1092 and 30-872, located respectively 230 metres and 440 metres south of the 2024 Mineral Resource Estimate (‘MRE’) model. Additional holes are planned in this resource expansion target area in the coming months over a surface of 450 metres by 550 metres, which we believe will add significant new tonnage to the MRE update, planned for Q1 2026. ‘
New analytical results are presented below (see Table 1), including 20 mineralized intercepts from 7 new drill holes. Infill intercepts are located inside the 2024 MRE model ( see November 14, 2024 news release ), and are focused on upgrading inferred mineral resources to measured or indicated categories, as applicable. Expansion intercepts are located outside the 2024 MRE model and may potentially lead to additional resources that will be classified appropriately within the next MRE update. Some of the reported intercepts have contiguous shallower infill as well as deeper expansion (noted on Table 1 below as ‘Both**’). Maps showing hole locations are available at www.osiskometals.com .
Highlights:
- Drill hole 30-1096
- 730.7 metres averaging 0.29% Cu (infill and expansion)
- Drill hole 30-1085
- 219.0 metres averaging 0.41% Cu (infill)
- 754.5 metres averaging 0.24% Cu (infill and expansion)
- Drill hole 30-1092
- 331.5 metres averaging 0.37% Cu (expansion)
- Drill hole 30-1095
- 309.5 metres averaging 0.26% Cu (infill)
- Drill hole 30-1098
- 115.0 metres averaging 0.29% Cu (infill)
- 124.5 metres averaging 0.20% Cu (expansion)
- Drill hole 30-1099
- 614.7 metres averaging 0.23% Cu (infill and expansion)
- Drill hole 30-0872
- 92.1 metres averaging 0.24% Cu (expansion)
- 47.2 metres averaging 1.14% Cu (expansion)
Table 1: Infill and Expansion Drilling Results
| DDH No. | From (m) | To (m) | Length (m) | Cu % | Ag g/t | Mo % | CuEq* | Type** |
| 30-0872 | 167.6 | 259.7 | 92.1 | 0.24 | 3.05 | 0.25 | Expansion | |
| And | 342.0 | 389.2 | 47.2 | 1.14 | 11.84 | 1.22 | Expansion | |
| 30-1085 | 3.0 | 222.0 | 219.0 | 0.41 | 2.79 | 0.44 | Infill | |
| And | 355.5 | 1110 | 754.5 | 0.24 | 1.63 | 0.019 | 0.32 | Both |
| (including) | 355.5 | 763.3 | 407.8 | 0.21 | 1.49 | 0.020 | 0.30 | Infill |
| (including) | 763.3 | 1110.0 | 346.7 | 0.27 | 1.79 | 0.019 | 0.36 | Expansion |
| 30-1092 | 15.0 | 346.5 | 331.5 | 0.37 | 3.21 | 0.39 | Expansion | |
| 30-1095 | 15.0 | 43.0 | 28.0 | 0.22 | 1.75 | 0.23 | Infill | |
| And | 57.0 | 366.5 | 309.5 | 0.26 | 2.11 | 0.007 | 0.30 | Infill |
| And | 425.9 | 482.0 | 56.1 | 0.23 | 1.70 | 0.24 | Expansion | |
| And | 524.7 | 550.5 | 21.9 | 0.42 | 2.04 | 0.43 | Expansion | |
| 30-1096 | 27.0 | 78.0 | 51.0 | 0.21 | 1.40 | 0.22 | Infill | |
| And | 129.0 | 177.0 | 48.0 | 0.17 | 1.20 | 0.18 | Infill | |
| And | 331.5 | 1062.2 | 730.7 | 0.29 | 1.60 | 0.032 | 0.42 | Both |
| (including) | 331.5 | 727.5 | 396.0 | 0.21 | 1.45 | 0.032 | 0.34 | Infill |
| (including) | 727.5 | 1062.2 | 334.7 | 0.39 | 1.79 | 0.032 | 0.52 | Expansion |
| 30-1098 | 36.0 | 141.0 | 104.5 | 0.20 | 2.25 | 0.21 | Infill | |
| And | 255.0 | 288.0 | 33.0 | 0.21 | 1.18 | 0.22 | Infill | |
| And | 330.0 | 445.5 | 115.0 | 0.29 | 2.18 | 0.017 | 0.36 | Infill |
| And | 606.0 | 730.5 | 124.5 | 0.20 | 1.57 | 0.014 | 0.26 | Expansion |
| And | 753.0 | 813.0 | 60.0 | 0.35 | 2.88 | 0.006 | 0.39 | Expansion |
| 30-1099 | 31.5 | 66.0 | 34.5 | 0.22 | 1.08 | 0.23 | Infill | |
| And | 105.3 | 720.0 | 614.7 | 0.23 | 1.59 | 0.016 | 0.30 | Both |
| (including) | 105.3 | 578.0 | 472.7 | 0.23 | 1.61 | 0.017 | 0.30 | Infill |
| (including) | 578.0 | 720.0 | 142.0 | 0.23 | 1.52 | 0.015 | 0.30 | Expansion |
| And | 862.2 | 1000.5 | 138.0 | 0.13 | 1.01 | 0.028 | 0.24 | Expansion |
* See explanatory notes below on copper equivalent values and Quality Assurance / Quality Control.
** ‘Both’ indicates drill holes that have contiguous shallower infill as well as deeper expansion intercepts.
Discussion
Drill hole 30-0872 was an old Noranda hole from the 1990s from which core was recovered and analyzed. The hole is located 440 metres south of the southern limit of 2024 MRE model and returned 92.1 metres averaging 0.24% Cu and 3.05 g/t Ag followed by a higher grade second intercept of 47.2 metres averaging 1.14% Cu and 11.8 g/t Ag (at the level of the C Zone skarn horizon), extending mineralization to a vertical depth of 390 metres. The first intercept starts at a depth of 168 metres and the overlying stratigraphy (Indian Cove hornfels) is unmineralized, but this waste material may be included as necessary strip in the next Whittle pit shell.
Drill hole 30-1085, located on top of Copper Mountain near the central part of the 2024 MRE model, intersected 219.0 metres averaging 0.41% Cu and 2.79 g/t Ag (infill), followed by a second intercept (starting 130 metres deeper) of 754.5 metres averaging 0.24% Cu, 1.63 g/t Ag and 0.019% Mo (both infill and expansion at depth).This hole extends mineralization near the centre of the deposit to a vertical depth of 1110 metres.
Drill hole 30-1092 is located 230 metres south of the southern limit of 2024 MRE model and returned 331.5 metres averaging 0.37% Cu and 3.21 g/t Ag (from surface down to the P4 stratigraphic level below the C Zone). This hole is located approximately 15 metres west of previously-reported hole 30-1067, which had failed to drill through a pillar of the B Zone.
Drill hole 30-1095, located in the south-central part of the 2024 MRE model, intersected 309.5 metres averaging 0.26% Cu and 2.11 g/t Ag (infill). This was followed by 56.1 metres averaging 0.23% Cu and 1.70 g/t Ag and then by another 21.9 metres averaging 0.42% Cu and 2.04 g/t Ag (both expansion), extending mineralization to a vertical depth of 550 metres.
Drill hole 30-1096, located in the central part of the 2024 MRE model, intersected two short (51 and 48 metre-long) mineralized zones, followed by 730.7 metres averaging 0.29% Cu, 1.60 g/t Ag, and 0.032% Mo (0.42% CuEq). The latter includes an expansion lower intercept, below the base of the 2024 MRE model, of 334.7 metres averaging 0.39% Cu, 1.79 g/t Ag, and 0.032% Mo (0.52% CuEq). This hole extends mineralization to a vertical depth of 1062 metres.
Drill hole 30-1098, located near the western margin of the 2024 MRE model, intersected 104.5 metres averaging 0.20% Cu and 2.25 g/t Ag (infill), followed by 115.0 metres averaging 0.29% Cu and 2.18 g/t Ag (infill). This was followed by 124.0 metres averaging 0.20% Cu and 1.57 g/t Ag and then by another 60.0 metres averaging 0.35% Cu and 2.88 g/t Ag (both expansion), extending mineralization to a vertical depth of 813 metres.
Drill hole 30-1099, located near the central part of the 2024 MRE model, adjacent to the Copper Mountain pit, intersected a short (34-metre-long) mineralized zone followed by 614.7 metres averaging 0.23% Cu, 1.59 g/t Ag, and 0.016% Mo (both infill and expansion), followed by a third intersection of 138 metres that averaged 0.13% Cu, 1.01 g/t Ag, and 0.028% Mo (expansion), extending mineralization in the porphyry core of the deposit to a vertical depth of 1000 metres.
Mineralization at Gaspé Copper is of porphyry copper/skarn type and occurs as disseminations and stockworks of chalcopyrite with pyrite or pyrrhotite and minor bornite and molybdenite. At least five retrograde vein/stockwork mineralizing events have been recognized at Copper Mountain, which overprint earlier prograde skarn and porcellanite-hosted mineralization throughout the Gaspé Copper system. Porcellanite is a historical mining term used to describe bleached, pale green to white potassic-altered hornfels. Subvertical stockwork mineralization dominates at Copper Mountain whereas prograde bedding-replacement mineralization, that is mostly stratigraphically controlled, dominates in the area of Needle Mountain, Needle East, and Copper Brook. High molybdenum grades (up to 0.5% Mo) were locally obtained in both the C Zone and E Zone skarns away from Copper Mountain.
The 2022 to 2024 Osisko Metals drill programs were focused on defining open-pit resources within the Copper Mountain stockwork mineralization ( see May 6, 2024 MRE press release ). Extending the resource model south of Copper Mountain into the poorly-drilled prograde skarn/porcellanite portion of the system subsequently led to a significantly increased resource, mostly in the Inferred category ( see November 14, 2024 MRE press release ).
The current drill program is designed to convert the November 2024 MRE to Measured and Indicated categories, as well as test the expansion of the system deeper into the stratigraphy and laterally to the south and southwest towards Needle East and Needle Mountain respectively. The November 2024 MRE was limited at depth to the base of the L1 skarn horizon (C Zone), and all mineralized intersections below this horizon represent potential depth extensions to the deposit, to be included in the next scheduled MRE update in Q1 2026.
All holes are being drilled sub-vertically into the altered calcareous stratigraphy which dips 20 to 25 degrees to the north. The L1 (C Zone) the L2 (E Zone) skarn/marble horizons were intersected in most holes, as well as intervening porcellanites that host the bulk of the disseminated copper mineralization.
Table 2: Drill hole locations
| DDH No. | Azimuth (°) | Dip (°) | Length (m) | UTM E | UTM N | Elevation |
| 30-0872 | 0.00 | -90.00 | 594.3 | 316531.1 | 5425181.2 | 706.3 |
| 30-1085 | 0.00 | -90.00 | 1110.0 | 316020.0 | 5426400.0 | 742.5 |
| 30-1092 | 0.00 | -90.00 | 741.0 | 316342.0 | 5425425.0 | 609.0 |
| 30-1095 | 0.00 | -90.00 | 696.0 | 316409.1 | 5425733.0 | 572.8 |
| 30-1096 | 0.00 | -90.00 | 1069.0 | 316198.0 | 5426305.0 | 753.3 |
| 30-1098 | 0.00 | -90.00 | 861.0 | 316034.0 | 5425948.0 | 600.5 |
| 30-1099 | 0.00 | -90.00 | 1041.0 | 315700.0 | 5426462.0 | 603.7 |
Explanatory note regarding copper-equivalent grades
Copper Equivalent grades are expressed for purposes of simplicity and are calculated taking into account: 1) metal grades; 2) estimated long-term prices of metals: US$4.25/lb copper, $20.00/lb molybdenum and US$24/oz silver; 3) estimated recoveries of 92%, 70% and 70% for Cu, Mo and Ag respectively; and 4) net smelter return value of metals as percentage of the price, estimated at 86.5%, 90.7% and 75.0% for Cu, Mo and Ag respectively.
Qualified Person
The scientific and technical content of this news release has been reviewed and approved by Mr. Bernard-Olivier Martel, P. Geo. (OGQ 492), an independent ‘qualified person’ as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects (‘NI 43-101’).
Quality Assurance / Quality Control
Mineralized intervals reported herein are calculated using an average 0.12% CuEq lower cut-off over contiguous 20-metre intersections (shorter intervals as the case may be at the upper and lower limits of reported intervals). Intervals of 20 metres or less are not reported unless indicating significantly higher grades . True widths are estimated at 90 – 92% of the reported core length intervals.
Osisko Metals adheres to a strict QA/QC program for core handling, sampling, sample transportation and analyses, including insertion of blanks and standards in the sample stream. Drill core is drilled in HQ or NQ diameter and securely transported to its core processing facility on site, where it is logged, cut and sampled. Samples selected for assay are sealed and shipped to ALS Canada Ltd.’s preparation facility in Sudbury. Sample preparation details (code PREP-31DH) are available on the ALS Canada website. Pulps are analyzed at the ALS Canada Ltd. facility in North Vancouver, BC. All samples are analyzed by four acid digestion followed by both ICP-AES and ICP-MS for Cu, Mo and Ag.
Option Grant
The Company announces that, effective August 12, 2025, it has granted to an employee of the Company an aggregate of 125,000 stock options (‘Options’) pursuant to the Osisko Metals omnibus equity incentive plan.
The Options have an exercise price of $0.44 per share and a five-year term from the date of grant, and vest annually in equal thirds beginning on the first anniversary of the date of grant.
About Osisko Metals
Osisko Metals Incorporated is a Canadian exploration and development company creating value in the critical metals sector, with a focus on copper and zinc. The Company acquired a 100% interest in the past-producing Gaspé Copper mine from Glencore Canada Corporation in July 2023. The Gaspé Copper mine is located near Murdochville in Québec ‘ s Gaspé Peninsula. The Company is currently focused on resource expansion of the Gaspé Copper system, with current Indicated Mineral Resources of 824 Mt averaging 0.34% CuEq and Inferred Mineral Resources of 670 Mt averaging 0.38% CuEq (in compliance with NI 43-101). For more information, see Osisko Metals’ November 14, 2024 news release entitled ‘Osisko Metals Announces Significant Increase in Mineral Resource at Gaspé Copper’. Gaspé Copper hosts the largest undeveloped copper resource in eastern North America, strategically located near existing infrastructure in the mining-friendly province of Québec.
In addition to the Gaspé Copper project, the Company is working with Appian Capital Advisory LLP through the Pine Point Mining Limited joint venture to advance one of Canada ‘ s largest past-producing zinc mining camps, the Pine Point project, located in the Northwest Territories. The current mineral resource estimate for the Pine Point project consists of Indicated Mineral Resources of 49.5 Mt averaging 5.52% ZnEq and Inferred Mineral Resources of 8.3 Mt averaging 5.64% ZnEq (in compliance with NI 43-101). For more information, see Osisko Metals ‘ June 25, 2024 news release entitled ‘Osisko Metals releases Pine Point mineral resource estimate: 49.5 million tonnes of indicated resources at 5.52% ZnEq’. The Pine Point project is located on the south shore of Great Slave Lake, NWT, close to infrastructure, with paved road access, an electrical substation and 100 kilometers of viable haul roads.
For further information on this news release, visit www.osiskometals.com or contact:
Don Njegovan, President
Email: info@osiskometals.com
Phone: (416) 500-4129
Cautionary Statement on Forward-Looking Information
This news release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Any statement that involves predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often, but not always, using phrases such as ‘expects’, or ‘does not expect’, ‘is expected’, ‘interpreted’, ‘management’s view’, ‘anticipates’ or ‘does not anticipate’, ‘plans’, ‘budget’, ‘scheduled’, ‘forecasts’, ‘estimates’, ‘potential’, ‘feasibility’, ‘believes’ or ‘intends’ or variations of such words and phrases or stating that certain actions, events or results ‘may’ or ‘could’, ‘would’, ‘might’ or ‘will’ be taken, occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. This news release contains forward-looking information pertaining to, among other things: the tax treatment of the FT Units; the timing of incurring the Qualifying Expenditures and the renunciation of the Qualifying Expenditures; the ability to advance Gaspé Copper to a construction decision (if at all); the ability to increase the Company’s trading liquidity and enhance its capital markets presence; the potential re-rating of the Company; the ability for the Company to unlock the full potential of its assets and achieve success; the ability for the Company to create value for its shareholders; the advancement of the Pine Point project; the anticipated resource expansion of the Gaspé Copper system and Gaspé Copper hosting the largest undeveloped copper resource in eastern North America.
Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management, in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including, without limitation, assumptions about: the ability of exploration results, including drilling, to accurately predict mineralization; errors in geological modelling; insufficient data; equity and debt capital markets; future spot prices of copper and zinc; the timing and results of exploration and drilling programs; the accuracy of mineral resource estimates; production costs; political and regulatory stability; the receipt of governmental and third party approvals; licenses and permits being received on favourable terms; sustained labour stability; stability in financial and capital markets; availability of mining equipment and positive relations with local communities and groups. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information are set out in the Company’s public disclosure record on SEDAR+ (www.sedarplus.ca) under Osisko Metals’ issuer profile. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/f12ebf89-5e37-4f45-86a2-3476365db1e2
https://www.globenewswire.com/NewsRoom/AttachmentNg/2a67e753-d0a2-4e74-8717-d7ee5bf555b7
News Provided by GlobeNewswire via QuoteMedia
This post appeared first on investingnews.com
The U.S. State Department’s annual human rights report delivered a grim assessment of conditions in Venezuela, declaring that human rights have fallen to a new low following reports of widespread abuses and state-sanctioned repression, particularly after the July 2024 presidential election when Nicolás Maduro clung to power.
‘The human rights situation in Venezuela significantly worsened,’ the report reads. ‘Throughout the year, and particularly after the July 28 [2024] presidential election, Nicolás Maduro and his representatives engaged in serious human rights abuses, reaching a new milestone in the degradation of the rule of law’ after the election, according to the U.N. Independent International fact-finding mission on the country in September.
According to the most recent State Department report, credible evidence indicates a dramatic escalation in arbitrary or unlawful killings, disappearances, torture and harsh prison conditions. NGOs and U.N. observers documented extensive restrictions on freedom of expression, with journalists and human rights defenders facing arrests, harassment and censorship. The judiciary remained deeply compromised — unable or unwilling to hold perpetrators accountable for abuses.
The report noted that the United Nations International Fact Finding Mission stated at least 25 people were killed in the first days following the July 2024 elections, including two children.
Pro-Maduro leaders ‘harassed and intimidated privately-owned and democratic opposition-oriented television stations, media outlets, and journalists’ through threats, property seizures and prosecutions.
The sweeping report, which will go public Tuesday afternoon, also calls out Brazil and South America for human rights abuses.
In a parallel diplomatic maneuver, the U.S. Department of Justice, backed by the State Department, significantly increased the reward for Maduro’s capture from $25 million to $50 million. Attorney General Pam Bondi accused Maduro of leading one of the world’s most notorious narco-trafficking operations, including associations with the Tren de Aragua, Sinaloa cartel and the infamous Cartel of the Suns. The Drug Enforcement Administration has reportedly seized 30 tons of cocaine linked to Maduro and his allies, with nearly seven tons directly tied to him.
This nullified the previous reward levels — $15 million initially set during Trump’s first term, later raised to $25 million under the Biden administration. Venezuela’s foreign ministry dismissed the bounty as a ‘political propaganda operation.’
The State Department report highlights an alarming absence of credible efforts by Venezuelan authorities to investigate or prosecute those responsible for human rights violations. Security forces, including the military, police, and colectivos — pro-Maduro armed groups — were repeatedly implicated in abuses, yet the justice system remained ineffective, allowing a culture of impunity to flourish.
Maduro was indicted in Manhattan court in 2020, during the first Trump administration, on narco-terrorism charges.
The dictatorial Venezuelan leader held onto power after the 2024 presidential election where the U.S. and much of Europe recognized his opposition as Venezuela’s duly elected president.
This post appeared first on FOX NEWS
U.S. Attorney Jeanine Pirro on Tuesday announced an indictment in Washington, D.C., accusing Jimmy ‘Barbecue’ Chérizier and Bazile Richardson, a naturalized U.S. citizen, of conspiring to send U.S. funds to finance Chérizier’s Haitian gang.
The Department of Justice (DOJ) said Chérizier is a fugitive and is believed to be in Haiti.
His co-defendant, Richardson, who also goes by ‘Fredo,’ ‘Fred Lion,’ ‘Leo Danger,’ and ‘Lepe Blode,’ was arrested in Pasadena, Texas on July 23.
Pirro said Tuesday that Chérizier is a gang leader who orchestrated and committed various acts of violence against Haitians.
In 2020, the U.S. sanctioned Chérizier under the Magnitsky Act for his alleged human rights violations. His indictment makes it the first of its kind for an individual sanctioned under the international Magnitsky Human Rights Accountability Act, Pirro added.
Richardson and Chérizier grew up together in Haiti, though the former later became a naturalized U.S. citizen and was living in North Carolina.
Richardson was indicted for allegedly sending money to Chérizier, knowing that he had been sanctioned under the Magnitsky Act.
‘I want to let the public know that anyone who was giving money to Chérizier, also known as Barbecue, because of his violent acts in his home country, cannot say ‘I didn’t know. I didn’t know that he was sanctioned by the U.S government,’’ Pirro said. ‘They will be prosecuted, and we will find them because they are supporting an individual who was committing human rights abuses. And we will not look the other way.’
The State Department’s Transnational Organized Crime Rewards Program announced Tuesday that it is offering a reward of up to $5 million for information leading to the arrest or conviction of Chérizier. Anyone with information about his whereabouts is encouraged to contact the State Department.
‘There’s a good reason that there’s a $5 million reward for information leading to Chérizier’s arrest. He’s a gang leader responsible for heinous human rights abuses, including violence against American citizens in Haiti,’ Pirro said. ‘The U.S. government sanctioned Chérizier in 2020 because he was responsible for an ongoing campaign of violence, including the 2018 La Saline massacre, in which 71 people were killed, more than 400 houses were destroyed, and at least seven women raped by armed gangs.’
Court documents show that Chérizier is a former officer in the Haitian National Police and leader of a gang known as the Revolutionary Forces of the G9 Family and Allies, which helped create a gang alliance called Viv Ansanm. The alliance united many of Haiti’s criminal gangs in opposition to the legitimate government of Haiti.
The indictment alleges Chérizier and Richardson, after Chérizier was sanctioned, led a wide-ranging conspiracy with people in the U.S., Haiti and other places to raise money for Chérizier’s gang activities, in violation of the sanctions.
Specifically, the two men solicited money from members of the Haitian diaspora in the U.S.
‘After sending funds to intermediaries in Haiti for Chérizier’s benefit, the U.S. and Haitian co-conspirators would send Chérizier images of receipts from money transfers,’ the DOJ said. ‘Chérizier used these funds principally to pay salaries to the members of his gang and to acquire firearms from illicit firearms dealers in Haiti.’
The Trump administration, in May, designated Viv Ansanm and Gran Grif – two of Haiti’s most powerful gang networks – as foreign terrorist organizations and specifically designated terrorists.
The move was aimed at disrupting the gangs’ operations and supporting efforts to restore order in the troubled Caribbean nation.
The designations brought serious legal consequences. Individuals or entities that provide material support to Viv Ansanm or Gran Grif could face criminal charges, loss of immigration benefits or removal from the U.S.
This post appeared first on FOX NEWS
Former first daughter Ashley Biden this week filed for divorce from her husband of 13 years, according to reports.
The 44-year-old also posted an Instagram story on the same day with the song ‘Freedom’ by Beyonce.
In her post, Biden walks through a park giving a thumbs up while the song plays, according to the Philadelphia Inquirer, which reported the filing first.
She also posted the quote: ‘New life, new beginnings means new boundaries. New ways of being that won’t look or sound like they did before’ over ‘Freedom Time’ by Lauryn Hill.
Biden has been married to plastic surgeon Howard Krein since 2012.
The estranged couple were wed in Greenville, Delaware, in a ceremony that combined her Catholic faith and his Jewish roots, according to People magazine.
A reception was held at the Biden family’s Wilmington lake house.
‘I kept telling Ash, we’ve got to open up the church and practice walking up and down the aisle so I can handle it,’ former President Joe Biden, who was vice president at the time, told People, saying he expected to be emotional at the ceremony.
‘This is the right guy. And he’s getting a helluva woman,’ the former president said at the time. Biden met her husband through her late brother Beau Biden and started dating him in 2010.
She mentioned her wedding when she introduced the former president at the Democratic National Convention last year.
‘At the time, my dad was vice president, but he was also that dad who literally set up the entire reception,’ she said. ‘He was riding around in his John Deere 4-wheeler, fixing the place settings, arranging the plants, and by the way, he was very emotional.’
She added, ‘Before he walked me down the aisle, he turned to me and said he would always be my best friend. All these years later, Dad, you are still my best friend.’
Fox News Digital has reached out to a rep for the former president for comment.
This post appeared first on FOX NEWS
More than 20 Republican attorneys general are demanding that the Trump administration reinstate safety protocols for the abortion drug mifepristone, saying it poses ‘serious risks to women.’
In a letter obtained by Fox News Digital, 22 attorneys general called on Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drugs Administration head Martin Makary to bring back safeguards for the pills that were scrapped by the Obama and Biden administrations.
‘Recent comprehensive studies of the real-world effects of the chemical abortion drug mifepristone report that serious adverse events occur 22 times more often than stated on the drug’s label, while the drug is less than half as effective as claimed. These facts directly contradict the drug’s primary marketing message of ‘safe’ and ‘effective,” the letter reads, citing studies published earlier this year by the Ethics and Public Policy Center (EPPA), a Washington, D.C.-based advocacy group.
The EPPA report claims the pill presents harm to women, causing 1 in 10 patients to experience a ‘serious adverse event,’ including hemorrhage, emergency room visits and ectopic pregnancy.
The letter, led by Kansas Attorney General Kris Kobach, comes after Kennedy Jr. asked Makary to review the latest data on mifepristone and its safety.
‘Based on that review, the FDA should consider reinstating safety protocols that it identified as necessary as recently as 2011 in its issuance of a Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, but which were removed by the Obama and Biden administrations,’ the letter reads, adding that the drug should be taken off the market if safeguards cannot be put in place.
‘Alternatively, in light of the serious risks to women who are presently being prescribed this drug without crucial safeguards, and in the event the FDA is unable to reinstate the 2011 safety protocols for mifepristone, the FDA should consider withdrawing mifepristone from the market until it completes its review and can decide on a course of action based on objective safety and efficacy criteria,’ the attorneys general wrote.
Sen. Josh Hawley, R-Mo., also sent a letter to Kennedy Jr. last month urging him to take immediate action to reinstate safety guardrails on mifepristone following the secretary’s commitment to conducting a safety review of the drug.
Makary had previously said that he had no plans to modify policies surrounding mifepristone but that the FDA would act if the data suggested there was a safety issue.
Mifepristone, which is taken with another drug called misoprostol to end an early pregnancy, was first approved by the FDA in 2000 after ‘a thorough and comprehensive review’ found it was safe and effective, according to the agency’s website, which noted that periodic reviews since its approval have not identified new safety concerns.
Last year, the Supreme Court rejected a challenge targeting the drug’s availability. The plaintiffs had sought to restrict access to mifepristone across the country, including in Democrat-led states where abortion remains legal. The court did not rule on whether the FDA acted lawfully when it moved during the Obama and Biden administrations to ease the rules for mifepristone’s use that had been established during the Clinton administration.
Medication abortions made up more than half of all abortions in the U.S. health care system in 2023, according to a study by the Guttmacher Institute.
‘Currently, a woman can obtain a mifepristone abortion by participating in only one telehealth visit with any approved healthcare provider (not necessarily a physician), ordering the drugs through a mail-order pharmacy, and self-administering them,’ the attorneys general wrote. ‘And the prescriber is only required to report an adverse event if he or she becomes aware that the patient has died.’
‘The FDA’s removal of these crucial safety protocols in 2016 (and in 2023) that only five years before the FDA considered necessary begs the question of whether the removal was motivated by considerations other than the safety of patients … The current FDA’s dedication to the health and wellbeing of all Americans is encouraging, as is the much-needed review of mifepristone that Secretary Kennedy has promised,’ the letter concludes.
This post appeared first on FOX NEWS
Former Navy SEAL and current GOP House lawmaker Rep. Eli Crane of Arizona delivered a pointed message to former President Barack Obama.
‘You’ve done enough damage. Probably best to sit this one out,’ the congressman told Obama in a post on X.
Crane made the comments in response to a post in which Obama declared, ‘Since we passed the Affordable Care Act, Republicans have tried over and over to repeal it. And over and over, they’ve failed — in part because millions of people now depend on the ACA for quality, affordable health care. Now Republicans are trying something different: quietly weakening the law and hoping you won’t notice. We can’t let them.’
GOP Sen. Mike Lee of Utah wrote in response to the Democrat’s post, ‘Obamacare was a great deal—for huge healthcare companies But it’s made healthcare less affordable for hardworking American families, who have seen their healthcare costs skyrocket—while a small handful of healthcare giants have reaped a windfall of billions of dollars a year.’
‘The worst part of Obamacare was putting able-bodied, working-age adults on government assistance instead of helping them find employment. I’ve been vocally against this since day one. Medicaid should be for needy children, families, and seniors. Not for those who can work!’ former Wisconsin Gov. Scott Walker, who is now the president of the Young America’s Foundation, wrote.
Fox News Digital reached out to the White House for comment on Obama’s post.
Obama served two consecutive terms as president, with his White House tenure spanning from early 2009 through early 2017, when he was succeeded by President Donald Trump.
This post appeared first on FOX NEWS